StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialAug 13, 2026, 07:37 AM

Clearmind Medicine CMND-100 AUD trial advances to Parts B & C

AI Summary

Clearmind Medicine Inc. announced that its independent DSMB has unanimously approved advancing the Phase I/II clinical trial for CMND-100 to Parts B and C. This follows the successful completion of Part A, where CMND-100 achieved its primary safety endpoint, demonstrating a favorable safety and tolerability profile in healthy participants. Parts B and C will evaluate CMND-100 in patients with Alcohol Use Disorder and healthy participants, marking a significant step towards a potential new treatment option.

Key Highlights

  • Independent Data and Safety Monitoring Board (DSMB) approved advancing CMND-100 clinical trial.
  • Trial for Alcohol Use Disorder (AUD) patients progresses to Parts B and C.
  • Part A successfully met its primary safety endpoint, showing favorable safety and tolerability.
  • Part B will evaluate CMND-100 in AUD patients for the first time.
  • Part B will enroll two cohorts of six patients receiving 80 mg and 160 mg doses.
  • Part C will evaluate CMND-100 at a fixed daily dose of 160 mg over five days in healthy participants.
  • CMND-100 is a non-hallucinogenic neuroplastogen-derived therapeutic for AUD.